CClinicalTrials.gg
Not yet recruitingNCT075134673T MRNUpdated Apr 7, 2026

3T Magnetic Resonance Neurography

An observational study in Healthy Adults, sponsored by Balgrist University Hospital. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Balgrist University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate whether optimized high-resolution MRI can better visualize very fine nerves in the cervical spine and neck region compared to standard MRI. The main question it aims to answer is:

Can high-resolution MRI reliably show small nerves and potentially detect their injuries or diseases that are often invisible on conventional MRI scans?

Participants will come once to Balgrist University Hospital for a one-hour visit. They will fill out a questionnaire and have a single 30-minute MRI scan of the cervical spine without contrast.

Read the detailed description

Diseases and injuries of the nerves in the area of the cervical spine and neck region are among the most common causes of pain in the neck, shoulder, and arm areas. To clarify the cause of the pain, an MRI examination of the neck region is therefore very often requested in order to visualize the nerves. However, some very fine nerves - in particular the smaller branches of the cervical nerves - are so thin that they can usually only be visualized incompletely or not at all reliably with conventional MRI techniques. As a result, injuries or diseases of some nerves frequently remain undetected, even though these nerves perform important motor functions - for example, the movement of the shoulder, the arm, or (in rare cases) also the diaphragm. Through modified and technically advanced MRI protocols (in particular high-resolution MR neurography), significantly better images can now be generated.

This study therefore investigates whether these special techniques can also clearly depict even very small nerves, so that these techniques can be applied in the future to patients with pathological changes and these changes can be better identified.

Participation involves a single visit to Balgrist University Hospital. The time commitment is one hour. Participants receive oral information about the project, complete a short questionnaire, and subsequently undergo the MRI examination. The time spent in the MRI scanner is approximately 30 minutes.

02

Conditions studied

  • Healthy Adults

Keywords

  • Cervical spine
  • MRI
  • 3 Tesla
  • Magnetic Resonance Neurograghy
  • Cervical nerves
03

In context

Lead sponsor

Balgrist University Hospital is the lead sponsor of 80 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers

Inclusion criteria

- written consent to agree to participate in this study

Exclusion criteria

Exclusion Criteria:

  • \<18 years of age
  • pregnancy
  • known cervical spine pathology or history of neck surgery
  • contraindication to perform non-contrast-enhanced MRI
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy volunteers

    Diagnostic Test: High-resolution three-dimensional magnetic resonance neurography protocols

Interventions

  • Diagnostic testHigh-resolution three-dimensional magnetic resonance neurography protocols

    Clinical standard three-dimensional magnetic resonance neurography sequences with high spatial resolution

06

What researchers measure

Primary outcomes

  1. Proportion of visible small-caliber nerve segments

    Visibility of small-caliber cervical nerves (phrenic, spinal accessory, dorsal scapular, vagus nerve) per segment (proximal, midsegment, distal) on both sides (left/right) per volunteer. Two board-certified radiologists with experience in MR Neurography will independently determine visibility (binary score: 0 = not visible, 1 = visible). Visibility is defined as continuous depiction of the nerve segment over its entire length with signal intensity clearly distinguishable from background tissue.

    Time frame: Within 12 weeks after MRI acquisition during radiological readout

Secondary outcomes

  1. Image quality score across different acceleration factors

    Image quality of small-caliber cervical nerves across varying acceleration factors will be independently assessed by two radiologists using a 4-point Likert scale (0 = poor/non-diagnostic, 2 = moderate, 3 = good, 4 = excellent).

    Time frame: Within 12 weeks after MRI acquisition during radiological readout

  2. Inter-reader agreement for visibility and image quality

    Reliability of visibility and image quality of small-caliber cervical nerves and nerve segments will be assessed by inter-reader agreement.

    Time frame: Within 12 weeks after MRI acquisition during radiological readout

  3. Frequency of anatomic variants

    Frequency of anatomical variants of small-caliber cervical nerves, reported as percentage of volunteers.

    Time frame: Within 12 weeks after MRI acquisition during radiological readout

07

Study locations

1 site
  • Balgrist University Hospital
    Zurich, 8008, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07513467
Lead sponsor
Balgrist University Hospital
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Jun 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Apr 7, 2026

Study contacts

Frederik Abel, MD
Contact
frederik.abel@balgrist.ch
+41 44 386 33 27
Reto Sutter, MD
Contact
reto.sutter@balgrist.ch
+41 44 386 33 08

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion